Donor lymphocyte infusion (DLI) can produce durable remissions in patients with chronic myelogenous leukemia (CML) who have a relapse after an allogeneic ...
Missing: decides | Show results with:decides
Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (alloSCT).
A total of 414 patients were treated with unrelated donor lymphocyte infusion for relapse after unrelated allogeneic bone marrow transplantation.
Missing: decides | Show results with:decides
The impact of donor lymphocyte infusion (DLI) initial cell dose on its outcome is known in patient with chronic myeloid leukemia, but limited in patients ...
Missing: decides | Show results with:decides
There was a tendency for a better outcome regarding the time from molecular relapse to first DLI for patients receiving DLI after six months post molecular ...
Nineteen of 39 patients (48.7%) with relapsed disease achieved remission after DLI. In this cohort, attaining T-FDC impacted favorably in disease control (76.7% ...
Patients who achieved molecular remission post-DLI had significantly improved survival when compared with those who failed to achieve molecular remission (95% ...
Jan 29, 2022 · Nineteen of 39 patients (48.7%) with relapsed disease achieved remission after DLI. In this cohort, attaining T-FDC impacted favorably in ...
Aug 27, 2019 · We present our study on the use of donor lymphocyte infusion (DLI) in relapsing patients after alloHSCT with a novel approach using the intra-bone (IB) route.
Whatever the indication for DLI, mortality related to post-DLI infusion is 5%–20%, and more than one-third of patients will develop acute and/or chronic graft ...